Registration Details
The fifth session in our Technology Partn3Ring webinar series will focus on new approach methodologies (NAMs) which are replacement technologies for use in assessing chemical or drug toxicity.
This webinar will include presentations showcasing in silico modelling approaches, a bioengineered bone organoid platform, an organ-on-chip system for inhalation toxicity assessment, and a human cardiac tissue model for preclinical drug development.
Learn more about the NAMs Technology Partn3Ring webinar series, including details of upcoming sessions and previous recordings.
Speakers and topics
Hear from four developers who will showcase their technologies with the potential to replace animal use in regulatory safety testing, and who are all looking to identify new partners for further development, qualification and use. There will be the opportunity to ask questions and connect directly with the developers to explore collaboration opportunities.
Closing the NAMs loop: Mechanism-based translation from plate to patient
Stephan Schaller (ESQlabs GmbH)
- ESQlabs develop PBPK/PBK and quantitative systems toxicology models to translate in vitro data into human exposure and effect predictions, supporting next-generation risk assessment.
- Stephan is seeking in vitro collaborators who can provide high-quality ADME and effect data to enable robust model parameterisation and ring trials across labs.
Advancing human-relevant inhalation toxicology and building evidence for the qualification of airway-on-chip NAMs
Joyce C.Y. Huang (Anivance AI)
- Anivance AI is developing an organ-on-chip-based NAM combining airway chips, a microphysiological system, and aerosol exposure to enable human-relevant inhalation toxicity assessment, reducing reliance on animal inhalation studies.
- Joyce is seeking pharmaceutical, biotech, and NAMs-focused partners for feasibility studies, cross-laboratory evaluation, and qualification-oriented development to advance regulatory science for inhalation drug development.
Title TBC
Jungwoo Lee (MetaBone)
- MetaBone has developed bioengineered human bone organoids powered by Demineralized Bone Paper technology, enabling scalable, high-throughput bone metabolism experiments to replace animal use.
- Jungwoo is seeking partners for pilot studies on novel drugs targeting bone disorders and malignancies, and strategic partners with drugs of known osteogenic or haematological cytotoxicity to benchmark the platform.
Title TBC
Barrett Downing (Imperial College London)
- Imperial College London has developed a cardiac platform combining a bioreactor with living myocardial slices derived from adult human hearts, replacing and reducing animal use in preclinical drug development.
- Barrett is seeking pharmaceutical and biotechnology partners to validate the platform through efficacy and toxicity studies of novel drug candidates.
About Technology Partn3Ring webinars
The NC3Rs Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development and use. Open to researchers, clinicians, pharmaceutical and industry professionals, each webinar features short pitches outlining 3Rs research, tools and technologies. Attendees can ask questions and connect with the speakers to access unique collaboration opportunities.